Evonik Industries AG · XETR:EVK

Evonik Industries — Q3 2017 Earnings Presentation

31 slides from Evonik Industries's earnings presentation, Nov 3, 2017

  1. Slide 1: Evonik Q3 2017 Earnings Conference Call

    Slide 1: Evonik Q3 2017 Earnings Conference Call

    Evonik Power to create. Q3 2017 Earnings Conference Call 3 November 2017 Christian Kullmann, Chief Executive Officer Ute Wolf, Chief Financial Officer 1

  2. Slide 2: Table of contents

    Slide 2: Table of contents

    Table of contents 1. Highlights Q3 2017 2. Financial performance Q3 2017 3. Outlook FY 2017 2 3 November 2017 | Evonik Q3 2017 Earnings Conference Call

  3. Slide 3: Q3 with another sequential earnings increase – Strong FCF

    Slide 3: Q3 with another sequential earnings increase – Strong FCF

    Q3 with another sequential earnings increase – Strong FCF Healthy trends in all segments, outlook specified Volume growth Adj. EBITDA Free Cash Flow Outlook Specified to +4 % €639 m €485 m upper half ) Broad-based volume growth; Another sequential Excellent cash generation in of adj. EBITDA range of

  4. Slide 4: Building a best-in-class specialty chemicals company

    Slide 4: Building a best-in-class specialty chemicals company

    Building a best-in-class specialty chemicals company First steps taken in execution of strategic agenda June Sept. Oct. Nov. 2017 2017 2017 2017 Strategy Update London “Building a best-in-class specialty chemicals company” Profitable Growth Huber Closing “Further balancing of Evonik’s portfolio and

  5. Slide 5: Consistently executing levers for structural uplift in profitability and growth

    Slide 5: Consistently executing levers for structural uplift in profitability and growth

    Building a best-in-class specialty chemicals company Consistently executing levers for structural uplift in profitability and growth Strategic lever Impact by (year) Synergy  Realization of synergies from Air Products €85 m 2020/ and J.M. Huber acquisitions EBITDA1 2021 realization Cost excellence

  6. Slide 6: Achieving cost excellence

    Slide 6: Achieving cost excellence

    Achieving cost excellence Leaner processes, higher cost discipline, competitive cost structures Cost savings of €200 m  Focus: Administrative & selling expenses €50 m  Scope: Management holding, segments & regions Immediate effect  Leaner organization and processes in 2018 of  Competitive cost s

  7. Slide 7: Table of contents

    Slide 7: Table of contents

    Table of contents 1. Highlights Q3 2017 2. Financial performance Q3 2017 3. Outlook FY 2017 7 3 November 2017 | Evonik Q3 2017 Earnings Conference Call

  8. Slide 8: Financial highlights Q3 2017

    Slide 8: Financial highlights Q3 2017

    Financial highlights Q3 2017 Positive volume and price trend, only modest NFD increase despite Huber Sales +12% Q3 16 vs. Q3 17 Adj. EBITDA (in € m) +11% (in € m) 3,556 / margin (in %) 578 639 3,164 Volume Price +4%   +3%  FX Other1 in % 18.3 18.0 Q3 16 Q3 17 -3%  +8%   Q3 16 Q3 17 +11% Adj. E

  9. Slide 9: Free cash flow Q3 2017

    Slide 9: Free cash flow Q3 2017

    Free cash flow Q3 2017 Excellent and broad-based free cash flow generation Operating cash flow Investing cash flow Free cash flow (cont. op. in € m) (cont. op. in € m)1 (cont. op. in € m)2 (before dividends and divestments) 727 485 509 289 Q3 2016 Q3 2017 Q3 2016 Q3 2017 -220  Strong Q3 cash flow t

  10. Slide 10: Resource Efficiency

    Slide 10: Resource Efficiency

    Resource Efficiency Sustained strong performance and margin level Sales (in € m) Adj. EBITDA (in € m) / margin (in %) +22% +19% 1,391 1,368 1,359 310 318 312 1,117 1,081 262 189 23.5 17.5 22.3 23.2 23.0 Q3 16 Q4 16 Q1 17 Q2 17 Q3 17 Q3 16 Q4 16 Q1 17 Q2 17 Q3 17  Another strong operational performa

  11. Slide 11: Nutrition & Care

    Slide 11: Nutrition & Care

    Nutrition & Care Healthy demand and improved market sentiment in Methionine Sales (in € m) Adj. EBITDA (in € m) / margin (in %) +3% -23% 1,093 1,124 1,151 1,101 239 1,066 209 196 189 184 22.4 19.1 16.8 17.0 16.7 Q3 16 Q4 16 Q1 17 Q2 17 Q3 17 Q3 16 Q4 16 Q1 17 Q2 17 Q3 17  Improved market sentiment

  12. Slide 12: Performance Materials

    Slide 12: Performance Materials

    Performance Materials Tightness in MMA and strong demand for intermediates drives Q3 performance Sales (in € m) Adj. EBITDA (in € m) / margin (in %) +15% +67% 972 916 919 169 174 797 846 159 104 98 13.0 11.6 16.4 18.4 18.9 Q3 16 Q4 16 Q1 17 Q2 17 Q3 17 Q3 16 Q4 16 Q1 17 Q2 17 Q3 17  Ongoing strong

  13. Slide 13: Table of contents

    Slide 13: Table of contents

    Table of contents 1. Highlights Q3 2017 2. Financial performance Q3 2017 3. Outlook FY 2017 13 3 November 2017 | Evonik Q3 2017 Earnings Conference Call

  14. Slide 14: Outlook for 2017 specified

    Slide 14: Outlook for 2017 specified

    Outlook for 2017 specified Upper half of guidance range expected Outlook Adj. EBITDA Significantly €2.4 bn higher sales Specified: (previously: higher sales; “upper half” Outlook €2.3 bn 2016: €12.7 bn) range Adj. EBITDA in €2.2 bn upper half of €2.2 and 2.4 bn range (2016: €2,165 bn) 2017E 14 3 Nov

  15. Slide 15: © evonik

    Slide 15: © evonik

    © evonik

  16. Slide 16: Additional indications for 2017

    Slide 16: Additional indications for 2017

    Additional indications for 2017  Air Products specialty Adj. EBITDA of around €250 m including first synergies of €10-20 m; Sales and adj. additives business EBITDA will be allocated roughly equally between N&C and RE  Huber Adj. EBITDA of around €15-20 m (for four month after closing on Sept 1st)

  17. Slide 17: Air Products specialty additives integration status

    Slide 17: Air Products specialty additives integration status

    Current status Air Products specialty additives integration: Already double digit million savings achieved as predicted Business continuity Integration Business / Processes / People / Systems Q1 2017 Q2 2017 Q3 2017 Q4 2017 2018 ff Transition and synergies Day 1 Leadership Summit Joint operating mod

  18. Slide 18: Huber Silica integration status

    Slide 18: Huber Silica integration status

    Current status Huber Silica integration: After successful Day 1 focus on systematic transition Business continuity Integration Business / Processes / People / Systems Q3 2017 Q4 2017 Q1 2018 Q2 2018 Q3 2018 ff Transition and synergies Day 1 Target Operating Model Combined IT fully realized  Acquisi

  19. Slide 19: Implementation schedule for acquisition synergies

    Slide 19: Implementation schedule for acquisition synergies

    Implementation schedule for acquisition synergies Ramp-up on track for Air Products specialty additives and Huber silica acquisitions Implementation schedule (in € m) Annual synergies One-time costs 110 Total 100 90 ~ €85 m p.a. (USD100 m) 80 Annual synergies APD: ~ €68 m p.a. (USD80 m) 70 Huber: ~

  20. Slide 20: Resource Efficiency Q3 2017 Business Line comments

    Slide 20: Resource Efficiency Q3 2017 Business Line comments

    Resource Efficiency Q3 2017 Business Line comments Sales (in € m) Coating Additives: Continued good development and high demand driven by waterborne coatings; selected end-markets like marine still a +22% bit weaker. 1,368 1,359 1,117 Crosslinkers: Strong demand in Composite and polyurethane dispers

  21. Slide 21: Nutrition & Care Q3 2017 Business Line comments

    Slide 21: Nutrition & Care Q3 2017 Business Line comments

    Nutrition & Care Q3 2017 Business Line comments Sales (in € m) Personal Care: Good development in Q3 with strong performance in +3% Specialty products and Active ingredients. Earnings also benefitted from acquired Dr. Straetmans business. 1,066 1,151 1,101 Health Care: Strong year across all product

  22. Slide 22: Performance Materials Q3 2017 Business Line comments

    Slide 22: Performance Materials Q3 2017 Business Line comments

    Performance Materials Q3 2017 Business Line comments Sales (in € m) MMA/ PMMA: Already restricted supply further tightened by competitors' outages in +15% Q3 and limited acetone availability (US) after Hurricane Harvey. 916 919 Ongoing healthy demand from automotive coatings and construction 797 con

  23. Slide 23: Net financial position development Q3 2017

    Slide 23: Net financial position development Q3 2017

    Net financial position development Q3 2017 (in € m) -€69 m -536 +727 -242 -3,087 -18 -3,156 Net debt position CF from Huber Silica Cash outs for Other Net debt position as of 30 June 2017 operating purchase price investments in as of 30 Sept. 2017 activities intangible (cont. op.) assets and PPE 23

  24. Slide 24: Net debt development

    Slide 24: Net debt development

    Net debt development (in € m) Net financial debt Pension provisions Total leverage1  Increase of net debt during 2017 mainly driven by acquisition-related purchase price payments (Air Products, Net 2,251 Dr. Straetmans, Huber Silica) 2,760 3,553 2,741 6,111 6,767 6,749 debt  Total leverage improve

  25. Slide 25: Adjusted income statement Q3 2017

    Slide 25: Adjusted income statement Q3 2017

    Adjusted income statement Q3 2017 in € m Q3 2016 Q3 2017 ∆ in % Depreciation & amortization:  Increase in D&A mainly as result of Air Products specialty additives Sales 3,164 3,556 +12 and Huber Silica purchase price allocation Adj. EBITDA 578 639 +11 Line item “D&A on intangible assets” Depreciati

  26. Slide 26: Cash flow statement Q3 2017

    Slide 26: Cash flow statement Q3 2017

    Cash flow statement Q3 2017 in € m Q3 2016 Q3 2017 CF from operating activities Income before financial result and income taxes 381 392  Strong operating cash flow in Q3 driven by Depreciation and amortization 178 213 higher earnings base, inflow from strict ∆ Net working capital 86 128 NWC managem

  27. Slide 27: Segment overview by quarter

    Slide 27: Segment overview by quarter

    Segment overview by quarter Sales (in € m) Q2/16 Q3/16 Q4/16 FY 2016 Q1/17 Q2/17 Q3/17 Nutrition & Care 1,111 1,066 1,093 4,316 1,124 1,151 1,101 Resource Efficiency 1,156 1,117 1,081 4,473 1,391 1,368 1,359 Perf. Materials 829 797 846 3,245 972 916 919 Services 163 173 180 683 193 174 172 Corporate

  28. Slide 28: Upcoming IR events

    Slide 28: Upcoming IR events

    Upcoming IR events Conferences & Roadshows Upcoming Events & Reporting Dates 6 November Roadshow, Frankfurt 6 March 2018 FY 2017 reporting 7 November Roadshow, London 8 May 2018 Q1 2018 reporting 14 November UBS European Conference, London 23 May 2018 AGM 22 November Exane Consumer Ingredients Confe

  29. Slide 29: Evonik Investor Relations team

    Slide 29: Evonik Investor Relations team

    Evonik Investor Relations team Tim Lange Janine Kanotowsky Head of Investor Relations Team Assistant +49 201 177 3150 +49 201 177 3146 tim.lange@evonik.com janine.kanotowsky@evonik.com Eva Frerker Daniel Györy Kai Kirchhoff Investor Relations Manager Investor Relations Manager Investor Relations Man

  30. Slide 30: Disclaimer

    Slide 30: Disclaimer

    Disclaimer In so far as forecasts or expectations are expressed in this presentation or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the oper

  31. Slide 31: © evonik

    Slide 31: © evonik

    © evonik

Source: Internet Archive copy of corporate.evonik.de

More decks from Evonik Industries AG

All 19 Evonik Industries decks